Gys1 maze therapeutics
WebFeb 10, 2024 · Taken together, the preclinical data support the potential for a GYS1 inhibitor, such as MZE001, as a treatment for Pompe disease. Based on these findings, … WebJul 8, 2024 · Regulatory News: Lysogene (Paris:LYS) (FR0013233475 – LYS), a gene therapy platform Company targeting central nervous system (CNS) diseases, today ann
Gys1 maze therapeutics
Did you know?
WebFeb 16, 2024 · Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that the company will present data from its first-in-human clinical trial of MZE001 in ... WebFeb 21, 2024 · Phase. Healthy. Drug: MZE001 Drug: Placebo. Phase 1. Detailed Description: Phase 1 study is designed to evaluate the safety, tolerability, …
WebMar 23, 2024 · Maze Therapeutics, which came out of stealth mode more than two years ago with $191 million in funding to translate genetic insights into new precision medicines, has revealed its first three lead therapeutic candidates … WebMar 22, 2024 · Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced new data from an exploratory muscle biopsy cohort of its Phase 1 clinical trial of MZE001 in ...
WebFeb 10, 2024 · Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced new preclinical data supporting the advancement of MZE001, which aims to address Pompe disease by reducing pathologic glycogen accumulation through the inhibition of muscle glycogen synthase (GYS1). WebMar 22, 2024 · GYS1 is an enzyme responsible for glycogen production. MZE001 is currently being evaluated as a potential oral treatment for patients with Pompe disease, …
WebFeb 27, 2024 · SOUTH SAN FRANCISCO--(BUSINESS WIRE)-- Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced positive results from the company’s Phase 1 clinical trial of MZE001 in healthy volunteers.MZE001, an oral glycogen synthase (GYS1) inhibitor that aims to address …
WebJul 5, 2024 · Maze Therapeutics. Aug 2024 - Present1 year 9 months. South San Francisco, California, United States. do your chewing teeth fall outWebFeb 10, 2024 · Pharmacology of small molecule inhibitors of GYS1 in canines and a mouse model of Pompe disease Data Summary: In in vivo mouse and canine models, inhibition … emergency vet clinic charleston wvWebFeb 17, 2024 · The latest longevity updates from our investment news desk. Maze completes Phase 1 trial. Precision medicine company Maze Therapeutics announced the completion of its first-in-human clinical trial of MZE001 in healthy volunteers. MZE001 is an oral glycogen synthase (GYS1) inhibitor that aims to address Pompe disease by limiting … do your children have the same blood typeWebJan 31, 2024 · Maze Therapeutics is a biopharmaceutical company applying advanced data science methods in tandem with a robust suite of research and development capabilities to advance a pipeline of novel precision medicines for patients with genetically defined diseases. do your children inspire youWebMar 22, 2024 · MZE001, a selective inhibitor of glycogen synthase 1 in muscle, is being developed to address this therapeutic gap. Maze has developed a novel biomarker, peripheral blood mononuclear cell (PBMC)... do your clothes say who you areWebDec 15, 2024 · SOUTH SAN FRANCISCO, Calif., December 15, 2024--Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced … emergency vet clinic cheektowaga nyWebSep 1, 2024 · The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Maze Therapeutics’ investigational product, MZE001, to treat Pompe disease. MZE001 is an inhibitor of oral glycogen synthase (GYS1). It could address Pompe disease by reducing disease-causing glycogen accumulation via substrate reduction … emergency vet clinic charlotte nc